Clonal hematopoiesis (CH) is described as the outsized contribution of expanded clones of hematopoietic stem and progenitor cells (HSPCs) to blood cell production. The prevalence of CH increases dramatically with age. CH can be caused by somatic mutations in individual genes or by gains and/or losses of larger chromosomal segments. CH is a premalignant state; the somatic mutations detected in CH are the initiating mutations for hematologic malignancies, and CH is a strong predictor of the development of blood cancers. Moreover, CH is associated with nonmalignant disorders and increased overall mortality. The somatic mutations that drive clonal expansion of HSPCs can alter the function of terminally differentiated blood cells, including the release of elevated levels of inflammatory cytokines. These cytokines may then contribute to a broad range of inflammatory disorders that increase in prevalence with age. Specific somatic mutations in the peripheral blood in coordination with blood count parameters can powerfully predict the development of hematologic malignancies and overall mortality in CH. In this review, we summarize the current understanding of CH nosology and origins. We provide an overview of available tools for risk stratification and discuss management strategies for patients with CH presenting to hematology clinics.
Skip Nav Destination
MYELODYSPLASTIC SYNDROMES IN THE AGE OF GENOMIC MEDICINE|
December 28, 2023
Causes and consequences of clonal hematopoiesis
Lachelle D. Weeks,
Lachelle D. Weeks
1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
2Center for Early Detection and Interception of Blood Cancers, Dana-Farber Cancer Institute, Boston, MA
3Department of Medicine, Harvard Medical School, Boston, MA
Search for other works by this author on:
Benjamin L. Ebert
Benjamin L. Ebert
1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
2Center for Early Detection and Interception of Blood Cancers, Dana-Farber Cancer Institute, Boston, MA
3Department of Medicine, Harvard Medical School, Boston, MA
4Howard Hughes Medical Institute, Boston, MA
Search for other works by this author on:
Blood (2023) 142 (26): 2235–2246.
Article history
Submitted:
August 18, 2023
Accepted:
October 25, 2023
First Edition:
November 6, 2023
Connected Content
A related article has been published:
The trajectory of prognostication and risk stratification for patients with myelodysplastic syndromes
A related article has been published:
Diagnosis and classification of myelodysplastic syndromes
A related article has been published:
Clinical decision-making and treatment of myelodysplastic syndromes
A related article has been published:
Introduction to a review series on myelodysplastic syndromes in the age of genomic medicine
Citation
Lachelle D. Weeks, Benjamin L. Ebert; Causes and consequences of clonal hematopoiesis. Blood 2023; 142 (26): 2235–2246. doi: https://doi.org/10.1182/blood.2023022222
Download citation file:
My Account
Sign In
December 28 2023
Advertisement intended for health care professionals
Cited By
Advertisement intended for health care professionals
This feature is available to Subscribers Only
Sign In or Create an Account Close Modal